Abcellera Biologics Inc
NASDAQ:ABCL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.39
5.97
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Abcellera Biologics Inc
Abcellera Biologics Inc
Additional Paid In Capital
Abcellera Biologics Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Additional Paid In Capital
$121.1m
|
CAGR 3-Years
174%
|
CAGR 5-Years
141%
|
CAGR 10-Years
N/A
|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Additional Paid In Capital
CA$7.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
53%
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Additional Paid In Capital
CA$5.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Innovotech Inc
XTSX:IOT
|
Additional Paid In Capital
CA$1.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
8%
|
|
Abcellera Biologics Inc
Glance View
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
See Also
What is Abcellera Biologics Inc's Additional Paid In Capital?
Additional Paid In Capital
121.1m
USD
Based on the financial report for Dec 31, 2023, Abcellera Biologics Inc's Additional Paid In Capital amounts to 121.1m USD.
What is Abcellera Biologics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
141%
Over the last year, the Additional Paid In Capital growth was 63%. The average annual Additional Paid In Capital growth rates for Abcellera Biologics Inc have been 174% over the past three years , 141% over the past five years .
You don't have any saved screeners yet
